Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0522213468
Fri, 29.04.2022
Achiko AG
Achiko AG - Publication of Annual Report and Annual Financial Statements 2021 to Occur by 31 May 2022
Zurich, 29 April 2022: Ad hoc announcement pursuant to Art. 53 LR - Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) ("Achiko", the "Company") announces that Achiko will publish its annual report and its annual financial statements for the y [ … ]
Thu, 28.04.2022
Achiko AG
AptameX Production and Commercialisation Update
- Company has commenced shipping and will book first sales in May 2022
- Reorganised production line able to meet stronger than expected demand for Achiko AG's innovative DNA aptamer saliva-based rapid test for Covid-19
- Validated calibration through quality control tests completed in Taiwan and [ … ]
Wed, 20.04.2022
Achiko AG
Achiko AG Signs Major Marketing and Sales Agreement with the World's Largest Islamic Association for its AptameX Covid-19 rapid test
Signed major deal with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta, for the use of Covid-19 test AptameX in general assemblies and activities. Located primarily in Indonesia, Nahdlatul Ulama is the world's larges [ … ]
Wed, 20.04.2022
Achiko AG
Achiko secures up to CHF12m equity and debt financing lines with RiverFort over 3 years
Zurich, 20 April 2022: Ad hoc announcement pursuant to Art. 53 LR - Achiko AG (SIX: ACHI; OTCQB:
ACHKF; ISIN CH0522213468) ("Achiko", the "Company") announces the completion of an Equity Subscription Agreement ("ESS") with the institutional investor RiverFort G [ … ]
Thu, 03.03.2022
Achiko AG
Achiko AG Production and Sales Update
- Unique chemistry with DNA Aptamers Completing pre-sales validation testing
- Completing pre-sales validation testing in Indonesia
Zurich, 3 March 2022: Ad hoc announcement pursuant to Art. 53 LR - Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) ("Achiko", the "Company") today announced an update [ … ]
Mon, 14.02.2022
Achiko AG
Achiko AG Research Paper and Commercialisation Update
- Calibration study results now available in draft paper on medRxiv, a preprint platform for health sciences, as "DNA Aptamer Gold Nanoparticle Colorimetric Diagnostic Test Kit of Saliva Samples for SARS-CoV-2 Virus Linked to Mobile Phone Application"
- AptameX is the world's first scale appl [ … ]
Thu, 27.01.2022
Achiko AG
Achiko AG strengthens senior team with appointment of Head of Corporate Development
- Achiko AG appoints David Hodge to the role of Head of Corporate Development in Switzerland
- David Hodge will oversee Corporate Affairs, and Strategic and Corporate Development
- Board Director Christophe Laurent to retire at month end
Zurich, 27 January 2022 [ … ]
Fri, 14.01.2022
Achiko AG
Achiko AG Reports Breakthrough Calibration Results for AptameX Covid-19 Rapid Test Technology
- AptameX(TM) Covid-19 rapid calibration successfully classified 100% of results indicating a likely > 97% Sensitivity and > 97% Specificity result in the first-generation test kits.
- Results were demonstrable both at CT values under 25, and betwe [ … ]
Fri, 31.12.2021
Achiko AG
Achiko AG completing CHF4.85m financing and changes to senior team
- Completing CHF 4.85 million placement from August 2021
- Board Director Christophe Laurent to retire
- Appoints Adam O'Keeffe as ad interim Chief Financial Officer
Zurich, 31 December 2021: Ad hoc announcement pursuant to Art. 53 LR - Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN [ … ]
Mon, 20.12.2021
Achiko AG
Achiko AG's Shares Begin Trading on the OTCQB Market
Company provides novel solution for Covid-19 testing gap with AptameX(TM), its highly effective and low-cost DNA aptamer-based technology for the detection of Covid-19 and its variants. AptameX represents the first massive use of DNA aptamers at scale versus classical antigenic approaches to rap [ … ]